[ad_1]
Continental clinical stage biopharmaceutical companies and Platinum Pharmaceuticals (new listing code: 02142) are offering shares. Based on data from multiple brokerage firms, as of Thursday (3rd) 6:50 pm, Hebo Pharmaceutical had recorded 5.849 billion yuan in its margin trade, 31.75 times excess. Among them, Futu Securities lent 1.35 billion yuan and Huatai Loan 1 billion yuan, Phillip lent 1 billion yuan.
Hebo Pharma plans to sell approximately 138 million shares, raising a maximum of 1.785 billion yuan, with an offer price ranging from 11.7 yuan to 12.92 yuan and an admission fee of 13,050 yuan for one lot (1,000 ) actions. The company will IPO from Monday (November 30) to Thursday (December 3) and will go public on December 10. Morgan Stanley, Bank of America and CITIC Securities are joint sponsors.
As of the first half of this year, the group recorded a loss of 48.31 million yuan (US dollars, the same below) and a loss of 37.52 million yuan in the same period last year; revenues in the first half of the year increased from 556,000 yuan to 60.7 million yuan. The group expects the net loss to increase at the end of this year, mainly due to continued clinical development of drug candidates and significant expenses.
To track IPO news, you can browse[IPO IPO]or use the gadget of IPO IPO
Related articles:[IPO]Pop Mart’s IPO rises to 4.68 billion yuan next Tuesday
Related articles:[L’elenco di Ant colpisce le rocce]Bloomberg: The chance to restart the IPO next year is slim
Download and use the “Hong Kong Economic Times” app for free and become a member, instantly receive the most accurate financial and current news and a variety of welcome gifts to choose from!
Publisher: Lai Yiling
[ad_2]
Source link
